Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06407232
PHASE3

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Sponsor: University of Wisconsin, Madison

View on ClinicalTrials.gov

Summary

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.

Official title: An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+/R-) Kidney and Kidney/Pancreas Transplant Recipients

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2024-08-08

Completion Date

2026-09

Last Updated

2025-10-08

Healthy Volunteers

No

Interventions

DRUG

Letermovir

480 mg taken orally once daily, for 84 days

Locations (1)

UW Hospital and Clinics

Madison, Wisconsin, United States